Question special

The discussion so far has underscored the utility of genomic information and the future of genomic medicine. How and when can we see genomic medicine impacting newborn screening tests? Since funding for these screens and therefore the breadth of disorders on the screening tests is administered at the state level in the US, what would it take to translate our genomic ability into practice? How have the conversations about information privacy shaped these decisions?

Side question: What is your vision for a newborn screen in the era of genomic medicine?